SMG
XLRN

Spectrum Management Group’s Acceleron Pharma XLRN Stock Holding History

Spectrum Management Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3
Closed – – 448
2017
Q3 		$0 Buy
+3
New +$104 ﹤0.01% 466

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Spectrum Management Group's XLRN Position: Q4 2017 in Review

Spectrum Management Group sold out of Acceleron Pharma (XLRN) in Q4 2017, closing a stake of 3 shares.

Spectrum Management Group first reported a position in XLRN in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 137 funds tracked by Wall St. Rank hold XLRN as of Q4 2017.

  • Spectrum Management Group reported no remaining Acceleron Pharma position as of Q4 2017 after selling out during the quarter.
  • Spectrum Management Group sold 3 Acceleron Pharma shares in Q4 2017.
  • Spectrum Management Group first reported a position in Acceleron Pharma in Q3 2017 and held it in 1 quarter.
  • Spectrum Management Group's Acceleron Pharma position peaked at $0 in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2017.

Based on Spectrum Management Group's 13F filing for Q4 2017, filed 7 Feb 2018.